Skip to main content
Log in

Lymphokine activated killer (LAK) cell mediated killing of human glioma: Effect of pretreating glioma with various membrane modifying agents

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The killing of human glioma by lymphokine activated killer (LAK) cells was studied. LAK cells generated by culturing recombinant interleukin-2 (ILr2) with human peripheral blood lymphocytes (PBL) obtained from normal volunteers markedly lysed allogeneic glioma grown in tissue culture. Susceptibility of glioma to lysis by LAK cells was abrogated by pretreating the glioma cells with trypsin or chymotrypsin, but was unaffected by pretreatment with hydrocortisone, neuraminidase, glycosidases or sodium periodate. These results suggest that the cell surface determinant on human glioma cells responsible for its tumor selective lysis by LAK is a protein sensitive to trypsin and chymotrypsin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Walker MD, Alexander Jr E, Hunt WE, Mc Carty CS, Mahaley MS, Mealy J, Norrell HA, Owens G, Ransohoff J, Nilson CB, Gehan EA, Stroke TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49: 333–342, 1978.

    Google Scholar 

  2. Walker MD, Green SB, Byar DP, Alexander JE, Batzdorf U, Brooke WH, Hunt WE, Mc Carty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosourea for the treatment of malignant glioma after surgery. New Engl J Med 303:1323–1329, 1980.

    Google Scholar 

  3. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine activated killer cell phenomenon lysis of natural interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841, 1982.

    Google Scholar 

  4. Jacobs SK, Kornblith PL, Wilson DJ, Grimm EA: In vitro killing of human glioblastoma by interleukin-2 activated autologous lymphocytes. J Neurosurg 64:114–117, 1986.

    Google Scholar 

  5. Rosenberg SA, Grimm EA, McCrogan N, Doyle M, Kawasaki E, Koths K, Mark DF: Biologic activity of recombinant human interleukin-2 produced in E. coli. Science 223, 1412, 1984.

    Google Scholar 

  6. Weinstein RS, Kornblith PL: Ultrastructure of a cloned astrocytoma in tissue culture. Cancer 27:1174–1181, 1971.

    Google Scholar 

  7. Dohan FC, Kornblith PL, Wellum GR, Pfeiffer SF, Levine L: S-100 protein and 2′,3′-cyclic nucleotide 3′-phosphohydrolase in human brain tumors. Acta Neuropathol (Berl) 40:123–128, 1977.

    Google Scholar 

  8. Trachtenberg MC, Kornblith PL, Hauptli J: Biophysical properties of cultured human glial cells. Brain Res 38:279–298, 1972.

    Google Scholar 

  9. Aynard-Henry M, Coleman MT, Dowdle WR, Lauer WG, Schild GC, Webster RG: Influenza neuraminidase and neuraminidase-inhibition test procedures. Bull Wld Hlth Org 48:199–202, 1973.

    Google Scholar 

  10. Burnet FM, Anderson SG: ‘T’ antigen of guinea-pig and human red cells. Australian J Exptl Biol Med Sci 25:213–217, 1947.

    Google Scholar 

  11. Gesner BM, Ginsberg V. Effect of glycosidases on the fate of transfused lymphocytes. Proc Nat Acad Sci USA 52:750–755, 1974.

    Google Scholar 

  12. Gasic G, Gasic T. Removal of PAS positive surface surgars in tumor cells by glycosidases. Proc Soc Exptl Biol Med 114:660–663, 1963.

    Google Scholar 

  13. Sedlacek HH, Seiler FR: Immunotherapy of neoplastic diseases with neuraminidase: Contraindications, new aspects, and revised concepts. Cancer Immunol Immunother 5:153–163, 1978.

    Google Scholar 

  14. Ravid A, Novogrodsky A: Kinetics of the induction of DNA synthesis in lymphocytes by periodate. Exptl Cell Res 97:1–5, 1976.

    Google Scholar 

  15. Schlager SI, Ohanian SH: Role of membrane lipids in the immunological killing of tumor cells: I. Target cell lipids. Lipids 18:475–482, 1983.

    Google Scholar 

  16. Gromkowski SH, Heagy W, Martz E: Blocking of the CTL-mediated killing by monoclonal antibodies to LFA-1 and Lyt-2,3. II. Evidence that trypsin pretreatment of target cells removes a non-H-2 molecule important in killing. J Immunol 134:70–77, 1985.

    Google Scholar 

  17. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA: Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 157:884–897, 1983.

    Google Scholar 

  18. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA: Interleukin-2 or autologous lymphokine activated killer cell treatment of malignant glioma: Phase I trial. Cancer Res 46:2101–2104, 1986.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobs, S.K., Parham, C.W., Holcomb, B. et al. Lymphokine activated killer (LAK) cell mediated killing of human glioma: Effect of pretreating glioma with various membrane modifying agents. J Neuro-Oncol 5, 5–10 (1987). https://doi.org/10.1007/BF00162760

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00162760

Keywords

Navigation